Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment

Abstract

Immunotherapy has revolutionised the treatment of cancers by exploiting the immune system to eliminate tumour cells. Despite the impressive response in a proportion of patients, clinical benefit has been limited thus far. A significant focus to date has been the identification of specific markers associated with response to immunotherapy. Unfortunately, the heterogeneity between patients and cancer types means identifying markers of response to therapy is inherently complex. There is a growing appreciation for the role of the tumour microenvironment (TME) in directing response to immunotherapy. The TME is highly heterogeneous and contains immune, stromal, vascular and tumour cells that all communicate and interact with one another to form solid tumours. This review analyses major cell populations present within the TME with a focus on their diverse and often contradictory roles in cancer and how this informs our understanding of immunotherapy. Furthermore, we discuss the role of integrated omics in providing a comprehensive view of the TME and demonstrate the potential of leveraging multi-omics to decipher the underlying mechanisms of anti-tumour immunity for the development of novel immunotherapeutic strategies.

PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer

“…A growing body of evidence has revealed the close relationship between the tumor microenvironment (TME) and the effectiveness of immunotherapy ( Donlon et al, 2021 ; Newnes et al, 2021 ). Immune checkpoint (ICP) inhibitors, including PD-1, CTLA4, LAG3, and TIM-3, have potent tumor suppressor effects and can interfere with immune escape; these inhibitors are currently the first-line treatment options for multiple malignancies ( Ribas and Wolchok, 2018 ; Tu et al, 2020 ).…”